HeraMED (ASX:HMD) has just announced a change to its board.
HeraMED, a medical data and technology company leading the digital transformation of maternity care, is pleased to announce the appointment of Emily Slade as a Non-Executive Director, with immediate effect.
Throughout her executive career, Emily has gained broad experience across Legal and Business Affairs, Intellectual Property and Strategy, in a range of sectors including healthcare, logistics and technology.
Emily has worked in a range of organisations from start-ups to SMEs as well as large public companies such as Ansell Limited.
Shares of HeraMED have fallen 2.564% following the announcement.
Any change in the make-up of a company?s board can have an impact on a company?s stock price.
Generally, age-related turnovers and voluntary resignations have a marginal impact on the share price.
However, when either the Chairman or another board member is ousted, this can have a significant impact on the stock price.
As the role of the board is to endorse the strategy of the business, changes to the board can have an impact on the strategic direction of the company and therefore it?s future profitability.